Consultation record
Submissions accepted — page 9
The submission is accepted and the draft is amended as proposed. The amendment is recorded in the amendment log of the document it changed and is traceable to the numbered submission.
Submissions
735 documents · page 9 of 25
Table 1. Submissions with this disposition, on this page.
| Reference | Consultation | Respondent | Point raised |
|---|---|---|---|
| DRAFT-SUPPLIERS-CO/013 | Draft supplier comparison table | Dr Anselm Thorsby-Nakamura | A field the Institute could not verify should be shown rather than omitted |
| DRAFT-SUPPLIERS-CO/014 | Draft supplier comparison table | Dr Hyacinth Drakeford-Amadi | The default ordering of a comparison table carries an implication |
| DRAFT-RETATRUTIDE-/001 | Draft monograph: retatrutide | Dr Eamon Immelmann | The analytical section assumes a reference standard that is not generally available |
| DRAFT-RETATRUTIDE-/004 | Draft monograph: retatrutide | Dr Lorcan Zaleski-Mbeki | The absence of a rare harm in the trial set is presented as reassurance |
| DRAFT-RETATRUTIDE-/005 | Draft monograph: retatrutide | Dr Wolfram Kaltenbach-Mensah | What happens when the compound is stopped is not addressed |
| DRAFT-RETATRUTIDE-/006 | Draft monograph: retatrutide | Dr Matthias Whitmarsh-Obi | Nothing is said about impaired renal or hepatic clearance |
| DRAFT-RETATRUTIDE-/007 | Draft monograph: retatrutide | Dr Liesbeth Zaleski-Mbeki | The pharmacokinetic section does not connect half-life to the dosing schedule |
| DRAFT-RETATRUTIDE-/009 | Draft monograph: retatrutide | Dr Jolyon Grünbaum-Sowande | A near-isobaric analogue is not distinguished by the identity determination described |
| DRAFT-RETATRUTIDE-/010 | Draft monograph: retatrutide | Dr Vasilisa Immelmann | The indication table mixes approved indications with uses for which the compound is merely supplied |
| DRAFT-RETATRUTIDE-/013 | Draft monograph: retatrutide | Dr Evander Ashworth-Danquah | The same concept is given three different names in one document |
| DRAFT-RETATRUTIDE-/014 | Draft monograph: retatrutide | Professor Chukwuemeka Rasmussen-Adeyemi | Glycaemic trials and weight-management trials are drawn on interchangeably |
| DRAFT-MELANOCORTIN/003 | Draft scoping review: melanocortin receptor agonists | Eamon Sandringham-Adu | The review does not say when it will be updated or what would trigger an update |
| DRAFT-MELANOCORTIN/004 | Draft scoping review: melanocortin receptor agonists | Thaddeus Isaksen-Balogun | A funnel plot is presented for a set too small to interpret it |
| DRAFT-MELANOCORTIN/006 | Draft scoping review: melanocortin receptor agonists | Dr Henrike Jastrzębska | The comparator was given at a dose below the one in general use |
| DRAFT-MELANOCORTIN/007 | Draft scoping review: melanocortin receptor agonists | Dr Lorcan Trelawney | Efficacy outcomes are rated for certainty and harms are not |
| DRAFT-MELANOCORTIN/010 | Draft scoping review: melanocortin receptor agonists | Dr Anselm Thorsby-Nakamura | Analytical surveys are treated as evidence about suppliers when they establish only what was in a… |
| DRAFT-MELANOCORTIN/011 | Draft scoping review: melanocortin receptor agonists | Dr Evander Ashworth-Danquah | An indirect comparison is presented without an assessment of transitivity |
| DRAFT-SEARCH-STRAT/001 | Draft search-strategy template for the synthesis series | Dr Jerome Petrossian | Interoperability with published certainty guidance must be preserved in any revision |
| DRAFT-SEARCH-STRAT/002 | Draft search-strategy template for the synthesis series | Dr Yusuf Whitmarsh-Obi | Protocol amendments are permitted without a requirement to record when they were made |
| DRAFT-SEARCH-STRAT/004 | Draft search-strategy template for the synthesis series | Dr Jozef Brandvold-Achterberg | The framework should say when a rating must not be issued at all |
| DRAFT-SEARCH-STRAT/008 | Draft search-strategy template for the synthesis series | Professor Bartolomeu Nkosi-Lindegaard | The assessment protocol is published after the assessment rather than before it |
| DRAFT-SEARCH-STRAT/010 | Draft search-strategy template for the synthesis series | Dr Vasilisa Immelmann | It is not clear which provisions bind the assessment committee |
| DRAFT-SEARCH-STRAT/011 | Draft search-strategy template for the synthesis series | Dr Adaeze Underhill-Okafor | Nothing prevents a conclusion stronger than its certainty rating |
| DRAFT-SEARCH-STRAT/014 | Draft search-strategy template for the synthesis series | Dr Ludmila Tollemache | Indirectness is defined so broadly that any evidence could be downgraded under it |
| DRAFT-SEARCH-STRAT/015 | Draft search-strategy template for the synthesis series | Dr Marisol Dunmore-Ekpo | The risk-of-bias instrument is not named, so a judgement cannot be reproduced |
| DRAFT-SEARCH-STRAT/016 | Draft search-strategy template for the synthesis series | Stellan Cholmondeley-Ade | The search date is not on the face of the document |
| DRAFT-SEARCH-STRAT/017 | Draft search-strategy template for the synthesis series | Ignatius Erlingsson | The four rating labels are not self-explanatory to a reader who meets them once |
| DRAFT-SEARCH-STRAT/018 | Draft search-strategy template for the synthesis series | Dr Vittoria Quintanilha | The framework does not say what new evidence would change a rating |
| DRAFT-PRINT-AND-AR/001 | Draft print and archival format for Institute documents | Dr Quentin Gwynne-Sarpong | A declared interest is published without being tested |
| DRAFT-PRINT-AND-AR/002 | Draft print and archival format for Institute documents | Dr Vasilisa Immelmann | There is no route to challenge a disposition |
page 9 of 25